Back to Search
Start Over
Gatifloxacin and Ethionamide as the Foundation for Therapy of Tuberculosis
- Source :
- Antimicrobial Agents and Chemotherapy. 47:2442-2444
- Publication Year :
- 2003
- Publisher :
- American Society for Microbiology, 2003.
-
Abstract
- The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice. Mice treated with GAT at 300 mg/kg of body weight in combination with ETA (25 mg/kg) for 5 days per week had sterile lungs, whereas mice treated with GAT (100 mg/kg) and ETA (25 mg/kg) had about 10 CFU/lung; however, there was regrowth of the organisms in both groups at the end of the observation period. When PZA (450 mg/kg 5 days per week) was added to the high-dose GAT-ETA regimen, no viable mycobacteria were present after the 8-week observation period. GAT in combination with ETA and PZA has great promise for the treatment of tuberculosis.
- Subjects :
- Tuberculosis
genetic structures
Antitubercular Agents
Drug resistance
Pharmacology
Gatifloxacin
Colony-Forming Units Assay
Mycobacterium tuberculosis
Mice
Anti-Infective Agents
Drug Resistance, Multiple, Bacterial
medicine
Animals
Experimental Therapeutics
Pharmacology (medical)
Ethionamide
Lung
Administration, Intranasal
Dose-Response Relationship, Drug
biology
business.industry
respiratory system
Pyrazinamide
biology.organism_classification
medicine.disease
eye diseases
Mice, Inbred C57BL
Dose–response relationship
Regimen
Infectious Diseases
Female
business
Fluoroquinolones
medicine.drug
Subjects
Details
- ISSN :
- 10986596 and 00664804
- Volume :
- 47
- Database :
- OpenAIRE
- Journal :
- Antimicrobial Agents and Chemotherapy
- Accession number :
- edsair.doi.dedup.....30d53db3d285a9eec34186d6dc66db0b